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Introduction 
Langerhans’ cell histiocytosis (LCH) is a proliferative 
histiocytic disorder of unknown origin. The lesions of LCH 
contain single or multifocal proliferation of histiocytes 
similar in phenotype to dendritic Langerhans’ cells (1). 
The disorder ranges in clinical severity from a solitary 
eosinophilic granuloma of bone to a generalised disease 
with multiple organ involvement. Primary involvement of 
the lung is rare and only few isolated cases have been 
reported (2). Occasionally, pulmonary LCH has been 
reported to be associated with Hodgkin’s disease (3); the 
underlying pathogenic mechanism of such association 
remains unknown. Here, we report the case of a 19-year-old 
patient who developed pulmonary LCH 2 months after 
receiving an autologous haemopoietic progenitor cell 
transplantation (AHPCT) for Hodgkin’s disease. 
Case Report 
A 19-year-old male presented with exertional dyspnoea. 
The patient had smoked one pack of cigarettes daily for the 
last 7 years. In 1991, he was diagnosed with nodular 
sclerosing Hodgkin’s disease with both mediastinal and 
right axilar lymph node involvement (stage III) and treated 
with six courses of chemotherapy and mantle radiotherapy. 
In 1994, he received three additional cycles of chemo- 
therapy because of recurrent Hodgkin’s disease. Due to the 
lack of response he was admitted to our hospital to be 
treated with an AHPCT. Before transplantation, he did not 
complain of respiratory symptoms, the chest X-ray was 
normal and pulmonary function tests were within normal 
limits. Intensive combination chemotherapy: BCNU 
558 mg (in day 6), VP-16 624 mg (days 5-2), cytarabine 
372 mg (days 5-2), and cyclophosphamide 5200 mg (days 
5-2), was used as conditioning regimen. Two months after 
transplantation, he noticed exertional dyspnoea. Physical 
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examination was unremarkable. Similarly, the haematologi- 
cal and biochemical values were within normal limits. Both 
chest X-ray and high resolution CT scan showed normal 
lung and media-stinal structures. Nevertheless, pulmonary 
function tests revealed a restrictive ventilatory pattern, 
together with reduced CO diffusing capacity (DLCO) and 
moderate hypoxaemia. An incremental exercise test showed 
a reduced exercise tolerance with marked decrease of 
arterial PO,. These functional abnormalities strongly sug- 
gested an underlying interstitial lung disorder associated 
with autologous transplantation. Fiberoptic bronchoscopy 
showed no macroscopic abnormalities. The differential cell 
count of bronchoalveolar lavage (BAL) fluid contained 
100% of alveolar macrophages and the percentage of CD,- 
positive cells reached 6% (normal ~3%) (4). Bacterial, 
acid-fast bacilli, Pneumocystis carinii stain and fungal 
cultures were negative. Histological examination of 
transbronchial biopsy specimens showed normal lung 
parenchyma. Due to the absence of specific diagnosis, an 
open lung biopsy was performed. 
The histopathological study of lung tissue showed a focal 
enlargement of the interstitial spaces containing large 
histiocyte-like cells with convoluted nuclei. Immunohisto- 
chemical study demonstrated positivity of these cells for 
protein S-100 (Fig. 1). We considered these findings diag- 
nostic of LCH. It is commonly accepted that conventional 
stainings are sufficient to suspect this lesion, and the 
positivity of convuluted histiocytic cells for C- 100 confirms 
the diagnosis of LCH (5). No evidence of pulmonary 
infection and/or a lymphoproliferative disorder was 
detected in any of the sections. The patient was initially 
treated with 60 mg/day prednisone that was slowly tapered 
(Fig. 2). At the present time, 2 yr after transplantation, he is 
without respiratory complaints and pulmonary function 
tests have improved substantially, although both a moder- 
ate reduction of DLCO and mild arterial 0, desaturation 
still persists during exercise. 
Discussion 
The most striking finding in the present case was the 
development of pulmonary LCH after AHPCT, which 
was not associated with detectable radiological signs 
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FIG. 1. (a) Photomicrograph of lung biopsy specimen 
showing thickening of interalveolar septa by accumulation 
of S-100 positive cells. (S-100, 100 x ). (b) Detail of large 
cells with convoluted nuclei showing positivity for S-100. 
(S-100, 630 x ). 
despite extensive granulomatous histological involvement. 
Pulmonary LCH has not been previously reported after 
autologous bone marrow transplantation of AHPCT. How- 
ever, development of pulmonary LCH after combined 
chemotherapy and radiotherapy for Hodgkin’s disease has 
been described in anecdotal cases (3). Although the exact 
mechanism of this association remains undecided, most 
authors suggest that both radiotherapy and chemotherapy 
might serve as a stimulus for abnormal proliferation of 
histiocytes (6-9). The singular involvement of the lung in 
our case is consistent with a reactive process following 
combined chemotherapy and mediastinal radiotherapy 
previous to AHPCT. However, there is no way to decide if 
this case represents a development of pulmonary LCH after 
AHPCT or if it was present before but accelerated by the 
procedure, as previously suggested (3). 
In pulmonary LCH, chest X-ray usually reveals a diffuse 
reticulonodular pattern with micronodules measuring 
2-5 mm in diameter and pulmonary cysts that predominate 
in the upper lobes (2,8). However, in occasional cases chest 
X-ray can be normal (14) and CT scan of the lung may 
disclose focal or diffuse abnormalities (10). In the present 
case, high resolution CT scan failed to demonstrate abnor- 
mal signs, despite the fact that this technique has shown to 
be the most sensitive for pulmonary LCH (11). We hypoth- 
esize that the small size of pulmonary nodular lesions in our 
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FIG. 2. Sequential evolution, before and after autologous 
haemopoietic progenitor cells transplantation (dashed 
line) of: (a) Forced vital capacity (FVC) and CO diffusing 
capacity (DLCO); (b) arterial PO, at rest and during 
exercise; (c) dashed area indicates the daily dose of 
prednisone. 
case was below the scan resolution (1 mm). It is of note that 
pulmonary function tests, including an incremental exercise 
test, were highly sensitive in detecting the functional impair- 
ment produced by the parenchymal lung disorder. Milburn 
et al. (12) have already highlighted the high sensitivity of 
lung function measurements in detecting pulmonary abnor- 
malities after bone marrow transplantation, even before the 
development of radiographical infiltrates. Therefore, as 
shown by the present case, it is highly recommendable 
to perform pulmonary function tests before and after 
autologous transplantation, in order to have a close 
follow-up of the clinical outcome of patients undergoing 
this procedure. Because of the high incidence of spon- 
taneous remission in untreated patients, the efficiency of 
different immunosuppressive therapeutic strategies for pul- 
monary LCH remains unknown (2). Several studies have 
reported the usefulness of corticosteroids with or without 
associated chemotherapy (13,14). Since that severe impair- 
ment of pulmonary function at the time of diagnosis has 
negative prognostic value in patients with Langerhans’ cell 
histiocytosis (15) an early intervention may be beneficial in 
terms of survival. In our patient, whose pulmonary function 
was closely monitored, we have shown substantial clinical 
and functional improvement after corticosteroid therapy 
and cessation of smoking (Fig. 2). 
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